Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival by Gustafsson, A. et al.
  
 2009;15:4742-4749. Published online June 30, 2009.Clin Cancer Res
 
Anna Gustafsson, Danuta Martuszewska, Martin Johansson, et al.
 
Carcinoma Reflecting Tumor Advancement and Survival
Differential Expression of Axl and Gas6 in Renal Cell
 
 
 
 
Updated Version
 10.1158/1078-0432.CCR-08-2514doi:
Access the most recent version of this article at: 
Material
Supplementary
 C1.html
http://clincancerres.aacrjournals.org/content/suppl/2009/06/15/1078-0432.CCR-08-2514.D
Access the most recent supplemental material at:
 
 
Cited Articles
 http://clincancerres.aacrjournals.org/content/15/14/4742.full.html#ref-list-1
This article cites 43 articles, 12 of which you can access for free at:
Citing Articles
 http://clincancerres.aacrjournals.org/content/15/14/4742.full.html#related-urls
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
 
 
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
.pubs@aacr.orgPublications Department at
To order reprints of this article or to subscribe to the journal, contact the AACR
Permissions
.permissions@aacr.orgDepartment at 
To request permission to re-use all or part of this article, contact the AACR Publications
 American Association for Cancer Research Copyright © 2009 
 on February 19, 2011clincancerres.aacrjournals.orgDownloaded from 
DOI:10.1158/1078-0432.CCR-08-2514
Differential Expression of Axl and Gas6 in Renal Cell Carcinoma
ReflectingTumorAdvancement and Survival
Anna Gustafsson,1DanutaMartuszewska,1MartinJohansson,2 Carl Ekman,1Sassan Hafizi,1
Bo« rje Ljungberg,3 and Bjo« rn Dahlba« ck1
Abstract Purpose: Overexpression of the receptor tyrosine kinase Axl is implicated in several cancers.
Therefore, we conducted this study to determine the expression of Axl and its ligand Gas6 in
various renal cell carcinoma (RCC) types and in oncocytoma.
Experimental Design: Real-time quantitative reverse transcription-PCR was used to quantify
tumor mRNA levels for Axl and Gas6 in a cohort (n = 221) of RCC patients. Serum levels of
soluble sAxl and Gas6 proteins were measured using specific ELISA assays (n = 282).The pres-
ence of Axl protein in tumor tissue was evaluated by immunohistochemistry (n = 294). Results
were correlated to tumor-associated variables, clinical biochemical tests, and patient survival.
Results: Tumor Axl mRNA levels correlated independently to survival when assessed against
tumor stage and grade. In the study group, themedian cancer-specific survival of all RCCpatients
during 307 months of follow-up was 55 months (confidence interval, F40.4). The 25% of
patients with lowest tumor Axl mRNA levels had significantly better survival than the rest (P =
0.0005), with 70% of the patients still alive at the end of follow-up. In contrast, in patients with
medium-high Axl mRNA, only 25% were alive at the end of follow-up.Tumor Gas6 mRNA levels
correlated to survival, tumor-associated variables, and disease severity as did serum levels of
soluble sAxl and Gas6 protein. However, no correlation between Axl protein in tumor tissue and
survival was found.
Conclusions: Axl and Gas6 expression in RCC are associated with tumor advancement and
patient survival. In particular, low tumorAxlmRNA levels independently correlatedwith improved
survival.
Renal cell carcinoma (RCC) represents f2% to 3% of all
human cancers (1), being the most common cancer of the adult
kidney (2). The prevalence is skewed between men and women
(1.5:1), and RCC incidence peaks at 60 to 70 years of age (3).
The only curative treatment of RCC is surgery (4). Today,
smaller and less advanced RCC tumors are detected by imaging
techniques, such as ultrasound and computed tomography,
and nephron-sparing surgery of tumors <4 cm in diameter is an
alternative that provides recurrence-free and long-term survival
rates (5). However, the outcome of metastatic RCC is poor and
mortality remains very high with a median cancer-specific
survival of 21 months (6, 7). Treatment of metastatic RCC,
in addition to removal of primary tumor and resection of
metastases, is palliative and includes systemic therapies, such as
immunotherapy (e.g., IFNa). Recently, a number of promising
tyrosine kinase inhibitors are approved both in the United
States and Europe for treatment of metastatic RCC (5).
RCC is composed of different tumor types, including
conventional or clear cell RCC (cRCC; representing the
majority of RCCs, 75-85%), papillary RCC (pRCC; 10-15%),
chromophobe RCC (chRCC; 4-5%), collecting duct carcinoma
(<1%), and unclassified RCC (5%; ref. 8). Inf4% to 5% of the
cases, benign oncocytoma is diagnosed when RCC is suspected
(9). The more aggressive types, cRCC and pRCC, originate from
the kidney tubular epithelium, whereas the less aggressive
chRCC and oncocytoma are derived from intercalated cells of
the collecting duct (9). The RCC types are classified based on
different histopathologic and specific genetic variations, where-
in alteration in the von Hippel-Lindau tumor suppressor gene is
one of the most common alterations responsible for cRCC,
occurring in f80% of these cases (9). Genetic alterations
taking place in hereditary pRCC involve mutations in the proto-
oncogenic receptor tyrosine kinase c-Met (10-15% c-Met
mutations in the sporadic form of pRCC; ref. 9).
Axl receptor tyrosine kinase is another proto-oncogene that is
abundantly expressed in human tissues (10) and, together with
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Tyro3 and Mer, constitutes the TAM family of receptor tyrosine
kinases that share the ligand Gas6 (product of the growth arrest
specific gene 6; refs. 11–13). Together these receptors regulate
many processes, such as cell proliferation, survival, cell adhesion,
migration, blood clot stabilization, inflammation, cytokine
release, and phagocytosis of apoptotic cells (10). Gas6 was
originally found as a gene induced in cells during growth arrest
(14). Axl was originally identified as a transforming gene in
chronic myeloid leukemia patients (15, 16) and in a chronic
myeloproliferative disorder (17) wherein Axl was suggested to be
capable of transforming cells without intrinsic activating muta-
tions. Axl has been shown to be overexpressed and to have
mitogenic and prosurvival roles in a broad spectrum of human
malignancies, e.g., breast, lung, colon, thyroid, and ovarian
cancers (18–22). Recently, Axl was shown to mediate glioma cell
proliferation, migration, and invasion (23), and in human
gliomas, both Axl and its ligandGas6 are frequently overexpressed
and predict poor prognosis (24). Moreover, Axl affects multiple
cellular behaviors required for neovascularization, such as
endothelial proliferation, migration, survival, and tube forma-
tion in vitro, and regulates angiogenesis in vivo (25). Axl is a
transmembrane protein, but soluble Axl (sAxl), consisting of the
proteolytically released extracellular domain (26), is present in
human serum as well (27). Gas6 is also present at low con-
centrations in circulation (27), and in both mouse and human
serum Gas6 circulates in complex with sAxl (26).4 The concentra-
tion profiles and biological implications of sAxl and Gas6 protein
in serum in RCC patients are, thus far, not investigated.
Axl and Gas6 expression in the human kidney is increased in
inflammatory renal disease (28), and based on a study of Axl
mRNA in 20 cases of cRCC, it has been proposed that Axl
mRNA levels are increased in cRCC tissue (29). We have now
conducted a large study to determine the expression of Axl and
its ligand Gas6 at the mRNA level in RCC. Moreover, we have
investigated the levels of sAxl and Gas6 protein in serum of
RCC patients, as well as the presence of Axl in tumor tissue by
immunohistochemistry.
Materials andMethods
Patient and primary RCC tumor information. The study included
308 RCC patients in total and was approved by the ethical committee of
Umea˚ University and the institutional review board. Each patient
participated after providing informed consent. Physical examination,
chest radiography, and computed tomography of the abdomen and
chest during the last years were used to evaluate clinical stage for the
patients. Tumor stage, after nephrectomy at the Department of Urology,
Umea˚ University Hospital, between the years 1982 and 2003, was done
according to the tumor-node-metastasis (TNM) classification system
2002 (30). The histopathologic nuclear grading was, according to
Skinner et al. (31), based on the worst nuclear grade. RCC type was
classified according to the Heidelberg consensus conference (2).
Clinicopathologic characteristics of patients and tumors are shown in
Table 1. Tumor size was defined as maximum diameter on computed
tomography. Venous involvement was defined as invasion of tumor
thrombus material in major renal veins and verified microscopically in
tissue slices from the renal hilum. Capsule involvement was defined as
invasion of the perinephric or renal sinus fat by tumor cells. None of
the patients were treated with any RCC-specific therapy before
nephrectomy. Among patients having metastatic disease at the time
of surgery, 19 had radiation therapy, 11 had metastases resected, 14
received IFN treatment, and 24 received hormonal therapy (medrox-
yprogesteron acetate or tamoxifen), whereas 25 patients only were
palliatively treated. In patients who recurred with metastatic disease
after surgery, 20 had surgical resection of metastases, 28 received first
line immunotherapy, 35 got hormonal therapy, 35 had radiation
therapy, and 1 patient had first line treatment with a tyrosine kinase
inhibitor (sunitinib), whereas the remaining patients only received
palliative treatments. Patients were followed up according to a
scheduled program, at least yearly by routine clinical follow-up, at
Umea˚ University Hospital or by contacting patients directly. The last
follow-up for all was conducted in June 2008. The follow-up time of
alive patients was 143.4 F 67.7 mo (n = 67). During the follow-up
period, 169 patients died of their disease, 72 died of other causes, 7
were alive with disease, and 60 were alive with no evidence of disease.
Preparation of tissue RNA. For the study of mRNA levels, tumor
samples from consecutive patients who underwent radical nephrectomy
for RCC, collected between 1985 and 2003, were obtained immediately
after surgical excision. The viable area of each tumor tissue was used for
extraction of high-quality RNA, using the TRIzol reagent (Invitrogen),
with the selection that only those having useful RNA could be included
in the study (n = 221). Histopathologically nonmalignant kidney cortex
tissue (n = 44), obtained furthest away from the tumor in the tumor-
bearing kidneys, was used for comparative evaluation. RNA integrity
was verified by ethidium bromide staining of 28S and 18S rRNA after
agarose gel electrophoresis and Bioanalyzer (Agilent Technologies).
RNA concentrations were quantified spectrophotometrically at a
wavelength of 260 nm (DU640 spectrophotometer, Beckman Coulter).
Each sample was rapidly frozen in liquid nitrogen and stored at -80jC
until analysis.
Quantitative real-time reverse transcription-PCR. One-step multi-
plex quantitative real-time reverse transcription-PCR (qRT-PCR) was
done using primary tumor total RNA from 221 RCC patients and using
total RNA from 44 matched histopathologically nonmalignant kidney
cortex tissue serving as a reference. Amplifications of gene of interest
and endogenous control gene were done in the same reaction tube.
Gene-specific primers and Taqman probes were purchased from
Applied Biosystems. To generate standard curves for quantitative
analysis of each gene, cell lines that were reliable and had verified
sources of mRNA for the particular gene were chosen. Tissue RNA was
extracted as described above, and total RNA for Axl and Gas6 standards
was extracted from cultured RCC 786-O cells (32) and stable Gas6-
transfected HEK293 cells (33), respectively, using CellDirect One-Step
qRT-PCR kit (Invitrogen). A master mix of Taqman MGB primers and
Translational Relevance
Renal cell carcinoma (RCC) has long been recognized as
a common tumor with dismal prognosis due to inadequate
therapy of metastatic RCC. Despite the increased under-
standing of the underlying oncogenic events in RCC, no
molecular markers are currently recommended for estima-
tion of prognosis. Herein, we report a large study of poten-
tial molecular primary tumor and serum markers in RCC,
namely the receptor tyrosine kinase Axl and its ligand
Gas6.BothAxl andGas6 expressionare shown tobe impli-
cated in RCC tumor advancement and severity and corre-
lated to patient survival. Furthermore, tumor Axl mRNA
was an independent factor in multivariate analysis when
assessed against RCC tumor stage and grade, wherein
low tumor Axl mRNAwas associated with longer patient
survival.
4 C. Ekman, M. Tjwa, J. Stenhoff, et al. Gas6 is inhibited by binding to the soluble
tyrosine kinase receptorAxl inhuman andmouse plasma, manuscript in preparation.
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probes, reverse transcriptase, and polymerase was prepared and mixed
with 40 ng sample RNA or with a series of known quantities standard
RNA in a final volume of 25 AL. The qRT-PCR reaction was done in an
ABI PRISM 7900HT system (Applied Biosystems), with the following
cycling conditions: reverse transcription for 15 min at 50jC, 2 min at
95jC, 40 cycles of 95jC for 15 s and 60jC for 60 s. Each measurement
was done in duplicate, and the threshold cycle (C t) value was
determined for each amplification curve. RNA template was omitted
in negative controls, and standard curves for both genes of interest and
housekeeping control gene were included in each run. From a screen
of 11 potential candidates, the human h2-microglobulin (B2M) was
selected as the most consistent and reliable reference gene in human
kidney samples (Supplementary Fig. S1A and B). For each sample, the
mean of duplicate C t values was converted to nanogram RNA from
linear regression analysis using the relative standard curve method.
Determined nanogram RNA values were then normalized to the
endogenous reference nanogram B2M content of the same sample.
Quantification of sAxl and Gas6 in human RCC serum. Concen-
trations of sAxl and Gas6 serum protein in 282 RCC patients and 65
normal serum samples, retrieved from the NOBIDA biobank,
established as a part of the Nordic Reference Interval Project (34,
35), was estimated using in-house developed ELISA assays specific for
sAxl and Gas6, respectively. Serum samples were routinely obtained
before any therapy from peripheral veins in fasting patients before
10 a.m. and stored at -80jC until analysis. Human sAxl and Gas6
serum levels were determined with sandwich ELISAs. The Gas6 ELISA,
using a polyclonal goat antibody (AB885, R&D Systems) as catcher
and biotinylated rabbit Gas6 antiserum as detector, was done as
described with small modifications; PBS was replaced with TBS, 1%
bovine serum albumin was replaced with 3% fish gelatin in TBS-
Tween 20 [50 mmol/L Tris, 150 mmol/L NaCl (pH 7.4) containing
0.1% Tween 20 and 3% fish gelatin; ref. 27]. In the ELISA for sAxl, an
immunoglobulin fraction of an in-house polyclonal rabbit antiserum
(denoted Axl-#042), raised against purified recombinant sAxl
expressed in a stable HEK293 cell line, was used as immobilized
catcher (in Maxisorp microtiter plates; Nunc). The biotinylated
immunoglobulin fraction of another in-house rabbit antiserum (Axl-
#041) was used as detector. The ELISA was done using the same
procedure as that described for the Gas6 ELISA (27). The details of the
recombinant sAxl expression and the detailed characterization of the
sAxl ELISA will be described elsewhere.5 In brief, all incubation steps
were carried out at room temperature, and every step was followed by
washes with TBS-Tween 20. Samples and reagents were diluted in TBS-
Tween 20 containing 3% fish gelatin. A dilution series of a known
concentration of the recombinant sAxl was used as a standard, and
wells with only TBS-Tween 20 with 3% fish gelatin were used as
negative controls. Samples were incubated overnight. For detection,
the plates were incubated for 1 h with 3 Ag/mL of biotinylated anti-
Axl-#041. After washes, the plates were incubated for 30 min with
StreptABC/HRP (Dako) before development with OPD (Dako) and
measurement of end point absorbance at 490 nm.
Immunohistochemical analysis of Axl staining in a tissue microarray of
RCC. A tissue microarray was constructed by taking two valid tissue
cores (0.6 mm) from each tumor block (n = 294) and by inserting them
into a recipient paraffin block (tissue microarray block). Each tissue
microarray block included 98 tissue cores (49 cases in duplicates).
Paraffin sections (4 Am) were deparaffinized and subjected to antigen
retrieval by boiling in 10 mmol/L citrate buffer (pH 6). The expression
of Axl was detected using the Axl-#042 antiserum (4.4 mg/mL total IgG)
at a dilution of 1:400. Immunohistochemical staining was done using
the DAKO Techmate 500 staining equipment including Envision as
secondary reagent, according to the instructions of the manufacturer
(DAKO). For nuclear counterstaining, hematoxylin was used. An
experienced pathologist evaluated the resulting staining pattern and
the staining intensity. Defective cores, i.e., cores with absent tissue, large
areas of necrosis, fat, and haemorrhages, and unstained cores, were
omitted from the analysis, rendering 173 tumors that were used for
analysis. Depending on staining intensity, Axl expression was divided
into three groups; no, low, and high (0-2). The specificity of the Axl-
#042 antiserum was evaluated by blocking specific Axl staining by
preadsorption of antiserum with an excess of sAxl antigen (Supple-
mentary Fig. S2A and B).
Statistical analysis. For statistical analysis of nonparametric data,
the Mann-Whitney U test and Spearman rank correlation test were
used. Survival curves were evaluated with the Kaplan-Meier method,
and cumulative survival data were compared using the log-rank test.
Multivariate prognostic analysis according to the Cox proportional
hazard regression model was done to evaluate intervariate indepen-
dence in relation to prognostic relevance. Survival time was measured
from the date of nephrectomy to the date of death or the latest follow-
up. All statistical tests were two sided, and the significance level was set
at 0.05. Statistical analyses were done using the SPSS software package
(version 16.0.2 for Macintosh; SPSS Institute). All assays were done
blinded to the study end point.
Results
Axl and Gas6 tumor mRNA levels in RCC. Axl and Gas6
tumor mRNA levels were determined with qRT-PCR in a large
cohort of RCC patients (n = 221), displaying a representative
distribution of RCC types (ref. 8; Table 1). Axl and Gas6 tumor
mRNA levels differed between RCC types and the levels found
in unaffected kidney cortex tissue (Fig. 1A and B). Thus, median
tumor Axl mRNA levels were increased in pRCC, whereas
median Gas6 mRNA was decreased in both pRCC and cRCC
Table 1. Patient information and clinicopathologic variables in relation to RCC subtype and oncocytoma
Variable pRCC cRCC chRCC Oncocytoma
Patients (%) 35 (11.4) 250 (81.2) 14 (4.5) 9 (2.9)
Patient sex %, male/female 65.7/34.3 59.2/40.8 50/50 55.6/44.4
Patient age range (median) 25-82 (65) 34-85 (67) 36-80 (66.5) 50-80 (66)
TNM stage I + II/III/IV 18/10/7 102/61/86 8/4/2 —
Nuclear grade 1/2/3/4 5/11/16/3 9/148/124/67 -/3/10/1 —
Tumor size mm range (median) 25-250 (70) 20-170 (80) 30-150 (88) 30-100 (40)
Vein invasion, no/yes 26/9 147/101 9/5 7/7-
Capsule invasion, no/yes 24/9 161/85 11/2 4/-
Survival (1)/(2) 51(-)/47 41 (F12.846)/42 -/86 -/100
NOTE: (1) indicates median survival months (CI), and (2) indicates the percentage of 5-y survival rate.
5 C. Ekman and B. Dahlba« ck. Identification and quantification of the soluble form of
the receptor tyrosine kinaseAxl in human plasma, manuscript submitted.
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(Fig. 1A). In contrast, in chRCC and oncocytoma, Axl mRNA
expression was very low, whereas Gas6 expression was slightly
higher than that of unaffected kidney cortex tissue (Fig. 1A). No
significant change of median expression of cRCC tumor Axl
mRNA could be detected (Fig. 1A). In cRCC, there was a
correlation between Axl and Gas6 mRNA levels (rs = 0.297, P <
0.001; Supplementary Fig. S3A). Another noteworthy observa-
tion in cRCC was that the tumor Axl and Gas6 mRNA levels
correlated positively with the Axl and Gas6 mRNA in their
respective matched kidney cortex samples [rs (Gas6) = 0.353,
P = 0.044 and rs (Axl) = 0.347, P = 0.048; data not shown].
Axl and Gas6 protein levels in RCC. The concentrations of
sAxl and Gas6 protein in serum did not correlate to tumor Axl
and Gas6 mRNA levels (Supplementary Fig. S4A and B), and
there were no differences in serum levels of sAxl and Gas6
between the different RCC types (data not shown). However,
compared with healthy controls, the serum concentrations of
sAxl protein were lower (Fig. 1C) whereas those of Gas6 were
higher in RCC (Fig. 1C), and the Gas6/sAxl ratios were higher
in RCC patients than in controls (Fig. 1D). Although Gas6
and sAxl protein were changed in different directions
compared with controls, there was a positive correlation
between the two in RCC patients (rs = 0.360, P < 0.001;
Supplementary Fig. S3B).
In immunohistochemical analysis, Axl staining was strong
in human normal kidney, in particular in tubular epithelial
cells (Supplementary Fig. S5D, right). In RCC tissue, Axl
staining varied considerably between individual cases where
no or both low and high intensities were found (Supplemen-
tary Fig. S5A-C and D, left). Of particular note, neither Axl
tumor mRNA nor sAxl serum protein concentrations correlat-
ed to the intensity of the Axl immunohistochemical staining
(Supplementary Fig. S6A and B).
Axl and Gas6 mRNA and protein levels in RCC patients
correlated with tumor associated clinical variables and biochem-
ical analytes. Correlation analyses were done to investigate
whether Axl and Gas6 tumor mRNA and/or protein levels were
related to clinicopathologic variables in patients with RCC
(Table 2). Increased sAxl and Gas6 protein levels in serum
correlated with more advanced tumor stage [P (Axl) = 0.037;
P (Gas6) = 0.010], with nuclear grade [P (Axl) = 0.018;
P (Gas6) < 0.001], and with tumor-thrombus extension factors
related with worse outcome (vein invasion; P (Axl) = 0.001;
P (Gas6) = 0.001), and furthermore, Gas6 also correlated with
renal capsule invasion in all tumors (P = 0.013). Decreased
tumor Gas6 mRNA levels correlated with more advanced tumor
stage (P = 0.03) and more aggressive nuclear grade (P = 0.014),
whereas no correlation between tumor Axl mRNA levels and
Fig.1. Axl and Gas6 tumormRNA and sAxl
and Gas6 serum protein in RCC. A and B,
Axl and Gas6 tumor mRNA expression in
various RCC subtypes and oncocytoma in
relation to unaffected kidney cortex tissues
(n = 44). Expressions in kidney tumors
(n = 221) according to subtype along with
respective median values. Levels were
determined by qRT-PCR and expressed in
arbitrary units as normalized against B2M
reference gene. ***, P < 0.001; **, P < 0.01;
*, P < 0.05. C, expression of sAxl and Gas6
protein in serum in various RCC subtypes
and in oncocytoma (t, tumors), in relation to
control human plasma (n, normal; n = 65).
Expressions in patient serum for all cancer
subtypes together (n = 282) along with
their median values. Levels were determined
byAxl-specific and Gas6-specific ELISA
assays, respectively, and are expressed in
absolute quantity of protein (ng/mL).
***, P < 0.001; *, P < 0.05. D, comparison of
the ratio of Gas6/sAxl serumprotein levels in
RCC (n = 282) compared with control
plasma (n = 65). Expression levels were
determined as described in C.
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tumor stage was found. No correlation between Axl immuno-
histochemical levels and any of the mentioned variables could
be detected (data not shown).
To estimate the systemic effects of the kidney tumors, because
paraneoplastic syndromes, including an abnormal liver func-
tion, anemia, low platelet count, and elevated erythrocyte
sedimentation rate, are found in f30% of patients with
symptomatic RCC (5), the levels of hemoglobin, albumin,
erythrocyte sedimentation rate, and C-reactive protein were
correlated to the levels of sAxl and Gas6 protein in serum.
Hemoglobin and albumin concentrations correlated negatively
to both the sAxl and Gas6 serum protein levels (P < 0.001;
Supplementary Fig. S7A and B). In contrast, erythrocyte
sedimentation rate and C-reactive protein correlated positively
to both sAxl and Gas6 serum protein concentrations (P < 0.001;
Supplementary Fig. S7C and D).
Axl and Gas6 tumor mRNA and patient survival. Median
cancer-specific survival of all RCC patients during 307 months
of follow-up was 55 months [confidence interval (CI),F40.39].
Although there was no simple linear relationship between RCC
Axl mRNA levels and survival (Supplementary Fig. S8A and B),
patients with the 25% lowest Axl mRNA stood out as a group
with longer survival than the rest of the patients (Fig. 2A;
Supplementary Fig. S8B). However, there was no difference in
survival between patients with medium and high tumor Axl
mRNA levels (Supplementary Fig. S8B). In the patient group
with medium and high tumor Axl mRNA levels, the median
survival during the follow-up was 40 months (CI, F10.91). In
Table 2. Tumor variables significantly associated with Axl and Gas6 tumor mRNA and serum levels of sAxl
and Gas6 proteins
Axl Gas6
Tumor mRNA (cRCC) Serum protein Tumor mRNA (cRCC) Serum protein
TNM stage — 0.126* 0.037 (273) -0.166* 0.030 (172) 0.155* 0.010 (274)
Nuclear grade 0.111 0.146 (173) 0.141* 0.018 (280) -0.187* 0.014 (172) 0.229c 0.001 (281)
Venous involvement — 0.197c 0.001 (278) -0.115 0.135 (171) 0.199c 0.001 (279)
Capsule involvement 0.085 0.268 (170) 0.096 0.113 (272) -0.105 0.176 (169) 0.151* 0.013 (273)
NOTE: Data given are as follows: Spearman correlation coefficient/P value (in italics)/number of cases (in brackets). Significant correlations are
in bold font.
*Correlation is significant at the 0.05 level (two tailed).
cCorrelation is significant at the 0.01 level (two tailed).
Fig. 2. LowAxl and high Gas6 tumor
mRNA levels correlate with longer survival.
A and C, Kaplan-Meier curve analyses of
patient survival in all RCC tumors and
oncocytoma based on Axl (A) and Gas6
(C) tumor mRNA. Axl mRNA (n = 221)
levels were divided into low (V25th
percentile) and medium/high (>25th
percentile), respectively. Gas6 mRNA
(n = 220) levels were divided into low
(V50th percentile) and high (>50th
percentile), respectively. B, Kaplan-Meier
curve analysis of patient survival exclusively
in cRCC tumors based on Axl tumor mRNA.
Axl mRNA (n = 173) levels were divided as
described in A. D, Kaplan-Meier curve
analysis of patient survival in all RCC tumors
and oncocytoma with selection forAxl
mRNA low cases (median division; V50th
percentile) and based on Gas6 tumor
mRNA. Gas6 mRNA (n = 111) levels were
divided as described in C. Patient survival is
shown in months, and percentage survival
for each group was compared using the
log-rank test (pooled over strata).Ticks,
censored cases. Significance of survival
difference (P) is depicted.
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contrast, in the ‘‘low Axl’’ group, 70% were alive at the end of
follow-up (Fig. 2A). The improved survival time in the low Axl
group was not a consequence of selection bias of less aggressive
chRCC or of oncocytoma, because the same results were
obtained in the specific cRCC group (P = 0.02; Fig. 2B).
In contrast to what we found for tumor Axl mRNA, increased
tumor Gas6 mRNA levels was associated with improved
survival (P = 0.037; Fig. 2C). In the ‘‘high Gas6’’ group the
median survival was 170 months (CI, undefined), whereas the
‘‘low Gas6’’ group had median survival of 38 months (CI,
F9.756). The combined Axl and Gas6 mRNA results yielded
additional information. Thus, when analyzing the influence of
Gas6 mRNA on survival in patients with either low or high
tumor Axl mRNA expression (median division), we found that
high tumor Gas6 mRNA further improved the survival of
patients with median low levels of tumor Axl mRNA, with
65% surviving at the end of the follow up (P = 0.018;
Fig. 2D). However, tumor Gas6 mRNA levels did not influence
the poor prognosis in patients with high tumor Axl mRNA levels
(data not shown). In agreement with the survival analysis,
patients that died of the disease had higher tumor Axl mRNA
levels (P = 0.032) and lower Gas6 mRNA levels (P = 0.021) than
those who stayed disease free (data not shown).
In multivariate prognostic analysis according to the Cox
proportional hazard regression model of tumor Axl and Gas6
mRNA, tumor Axl mRNA remained as an independent
prognostic factor in relation to cancer-specific survival (P =
0.004; CI, 1.278-3.712) whereas tumor Gas6 mRNA lost its
prognostic information (Table 3).
Axl and Gas6 protein levels and patient survival. The levels of
sAxl and Gas6 protein in serum from RCC patients correlated
negatively to survival, i.e., having lower serum levels was
beneficial for the patients [P (sAxl) = 0.048, P (Gas6) = 0.038;
Fig. 3A and B]. Furthermore, serum levels of both sAxl and Gas6
protein were higher in RCC patients who died of the disease
than in those who stayed alive and disease free [P (sAxl) =
0.014, P (Gas6) = 0.007; Fig. 3C and D]. Noteworthy, the
intensity of Axl staining in tumor tissue did not correlate to
survival (data not shown).
Discussion
RCC is characterized by a variable clinical course and known
for its unpredictable behavior (5, 9). Therefore, it is of great value
to identify the fundamental molecular basis for the biological
events underlying individual tumors. The 2002 TNM staging
classification system (30), the Fuhrman grading system (36), and
the histologic subtyping into different kidney tumors are
generally accepted as the most important prognostic factors
(5). However, it is currently unclear whether this system is
optimal for prediction of survival in RCC. There have been
considerable efforts to find othermarkers conclusively associated
with risk of progressive disease. Markers currently under
investigation are carbonic anhydrase IX, vascular endothelial
growth factor (VEGF), hypoxia inducible factor, Ki67, p53, PTEN,
E-cadherin, and CD44 (5). However, none of them is presently
recommended for use in clinical routine, and thus, there is a great
need for reliable prognostic and predictive markers.
In this report, low tumor Axl mRNA was shown to be an
independent prognostic factor for RCC. Moreover, high tumor
Gas6 mRNA was associated with improved survival. Combining
Axl andGasmRNA levels further defined a population of patients
having low Axl and high Gas6 mRNA levels and good prognosis.
The positive effects of high tumor Gas6 mRNA, together with the
contrary expression patterns of tumor Axl and Gas6 mRNA in
RCC, are intriguing because it has been shown in human glioma
that high tumor Axl and Gas6 mRNA levels indicated worse
prognosis (24) and because of observations that Gas6 binding
to Axl stimulates proliferation and survival (37–39). Thus far,
increased Gas6 mRNA correlating with favorable prognosis has
only been reported in human breast cancer (40). Furthermore, in
cRCC, tumor Axl mRNA levels were broadly distributed and the
results are consequently more informative than those of a
previous study of 20 patients that suggested Axl mRNA levels
to be significantly up-regulated in cRCC (29). A methodologic
difference that possibly can explain the divergent results is that
tumor Axl mRNA was semiquantitatively estimated after RT-PCR
by gel electrophoresis in the previous study, whereas we have
used quantification by qRT-PCR.
Axl/Gas6 signaling is involved in directed cell migration of
smooth muscle cells in the context of remodeling of the vessel
wall after vascular injury and for endothelial cells during tumor
angiogenesis (25, 41). Thus, Axl has recently been shown to
affect multiple cellular behaviors required for neovasculariza-
tion in vitro , and loss of Axl expression in tumor cells blocked
the growth of solid human neoplasms in an in vivo breast
carcinoma model (25). As such, this angiogenic potency of Axl/
Gas6 signaling might contribute to tumor progression in RCC,
wherein vascularization plays an important role (9) and could
be one explanation for a worse outcome of patients with higher
Table 3. Multivariate prognostic analysis according to the Cox proportional hazard regression model
Exp(B) P 95% CI for Exp(B)
Prognostic factor
Tumor Axl mRNA 2.107 0.007 1.231-3.605
Tumor Gas6 mRNA 1.258 0.248 0.852-1.856
Age (<65 y, >65 y) 0.754 0.148 0.515-1.105
Sex (male versus female) 1.280 0.216 0.866-1.893
Tumor diameter (<80 mm, >80 mm) 1.082 0.683 0.742-1.577
Grade (I + II versus III + IV) 1.414 0.196 0.836-2.394
Stage (I + II versus III + IV) 12.143 <0.001 6.666-22.121
After final stepwise analysis
Tumor Axl mRNA 2.178 0.004 1.278-3.712
Stage (I + II versus III + IV) 12.095 <0.001 6.858-21.332
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Axl mRNA levels. Still intriguing is the observation that high
tumor Gas6 mRNA levels correlated with longer survival.
Recently, Gas6 via Axl was shown to have inhibitory effects on
the VEGF receptor–driven angiogenic program (42), the
importance of which, especially in cRCC angiogenesis wherein
the majority of cases are von Hippel-Lindau–defective with
increased levels of hypoxia-inducible factor-a target genes such
as VEGF (9), is well known (43, 44). Therefore, high RCC Gas6
mRNA levels could be beneficial by possibly inhibiting this
VEGF-driven angiogenesis. Furthermore, prolonged Gas6 stim-
ulation results in Axl internalization and lysosomal degradation
(45), and this Gas6-dependent Axl down-regulation over time
could possibly contribute to the better prognosis of RCC
patients with high tumor Gas6 levels.
Unfortunately, we cannot report any information about the
phosphorylation status of Axl in tumor tissues, which would
be informative with respect to receptor activation. However, it
should be emphasized that it was Axl at the mRNA level that
correlated to survival time of RCC patients and that Axl protein
in tumor tissue did not.
The Gas6 system has been implicated in primary haemo-
stasis, and Gas6-/- mice are rescued from induced thrombosis
(46). Possibly, the skewed balance between sAxl and Gas6
protein in serum and, thus, the assumed risk of increased
thrombus formation, likewise the various correlations of sAxl
and Gas6 serum protein to several tumor risk factors, could
contribute to the poor outcome of patients with RCC. Indeed,
lower levels of sAxl and Gas6 protein in serum correlated to
longer survival in RCC patients. Furthermore, we have verified
that Gas6 protein in serum is correctly g-carboxylated (data not
shown), as Gas6 that is not would not be functional. The
mechanisms regulating the shedding of sAxl protein from cells
and the Gas6 protein levels in serum under healthy conditions
and in malignancies are unknown. We find it unlikely that
the sAxl and Gas6 protein in the serum of RCC patients were
derived from the tumor tissue because there were no
correlations between Axl and Gas6 mRNA levels in RCC and
corresponding sAxl and Gas6 protein levels in serum. Possibly,
sAxl and Gas6 are derived from endothelial cells, fibroblasts,
and/or vascular smooth muscle cells (13) and aberrantly
released into the circulation in response to the disease.
In conclusion, we report that tumor Axl and Gas6 mRNA
levels and sAxl and Gas6 serum protein levels correlated to
survival of patients with RCC. Particularly noteworthy was the
observation that low tumor Axl mRNA in RCCs at time of
nephrectomy remained as an independent survival factor after
multivariate prognostic analysis. Altogether, our study contrib-
utes to a greater understanding of the complicated pathobiology
of RCC, wherein the discovery of new molecular markers for use
in prognosis and/or medical intervention is highly desired.
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Fig. 3. Low sAxl and Gas6 serum protein
levels in RCC correlate with longer survival.
A and B, Kaplan-Meier curve analysis of
patient survival in all RCC tumors and
oncocytoma based on sAxl (A) and Gas6
(B) protein in serum, respectively. sAxl
(n = 282) andGas6 (n = 283) protein levels
were divided into low (V50th percentile)
and high (>50th percentile) categories.
Patient survival is shown in months, and
percentage survival for each group was
compared using the log-rank test (pooled
over strata).Ticks, censored cases.
Significance of survival difference (P) is
depicted. C and D, comparison of sAxl (C)
and Gas6 (D) protein expression levels
in serum of RCC patients who stayed alive
and disease-free after tumor nephrectomy,
with those levels in RCC patients who
had their tumor removed, but eventually
died of the disease. Quantifications of sAxl
[n(alive) = 55, n(died of disease) = 159]
and Gas6 [n(alive) = 55, n(died of
disease) = 160] protein concentrations in
serumwere determined by use of
Axl-specific and Gas6-specific ELISA
assays, respectively, and are expressed in
absolute quantity of protein (ng/mL).
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